ADVFN - Advanced Financial Network.
HOME» NYSE » M » MDT Stock Price » MDT Stock News

Medtronic Share News

 Medtronic, Inc. Stock Price
MDT Stock Price
 Medtronic, Inc. Stock Chart
MDT Stock Chart
 Medtronic, Inc. Stock News
MDT Stock News
 Medtronic, Inc. Company Information
MDT Company Information
 Medtronic, Inc. Stock Trades
MDT Stock Trades

St Jude Defibrillator Lead Performed Worse Than Competitor Lead -Study

By Anjali Athavaley Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- St. Jude Medical Inc.'s (STJ) Riata defibrillator leads performed significantly worse than Medtronic Inc.'s (MDT) Quattro leads, according to results from a multicenter study presented at a medical meeting Thursday. St. Jude stopped selling the Riata leads in 2010, but about 79,000 are still implanted in patients in the U.S. St. Jude said last year it was recalling them due to a tendency for the metal wires to wear through their silicone covering. Data in the study, presented at the Heart Rhythm Society meeting in Boston, was collected retrospectively from seven centers. Researchers evaluated the leads for all causes of failure, including cases where cables wore through their coating and electrical malfunctions. Riata, but not Riata ST, leads performed significantly worse than Quattro, according to the study. But follow-up for Riata ST was shorter than it was for Riata. The study also found that nearly a third of leads with exposed cables were malfunctioning. St. Jude said in a statement that the data is consistent with the company's findings that significant design changes implemented in the Riata ST leads resulted in improved performance compared to the Riata leads. In March, a study authored by Robert G. Hauser, a Minnesota cardiologist, tied a malfunction in Riata to at least 20 deaths. Dr. Hauser said the deaths alleged from Riata malfunctions were about nine times greater than Quattro. Last month, St. Jude said it was seeking a retraction of the study, published in the Heart Rhythm Journal. The company says Dr. Hauser undercounted deaths linked to Quattro. St. Jude shares were up 2.3% to $40.12 in recent trading. The stock is down 24% in the last year. -By Anjali Athavaley, Dow Jones Newswires; 212-416-4912;

Stock News for Medtronic (MDT)
05/27/201519:13:02Here's What David Einhorn's $7.7 Billion Hedge Fund Has Been...
05/27/201516:21:09Specialized Disclosure Report (sd)
05/21/201515:42:40Medtronic CEO Omar Ishrak to Speak at Sanford Bernstein Strategic...
05/20/201512:15:10What Is the S&P 500 Index?
05/20/201510:40:00China Diabetes Management Devices Market Growth to be Driven...
05/20/201510:40:00China Diabetes Management Devices Market Growth to be Driven...
05/20/201509:30:15Medtronic Drug-Coated Balloon for Treatment of Peripheral Arterial...
05/19/201510:10:11Medtronic Expects Profit at High End of Outlook
05/19/201509:58:11Medtronic Expects Profit at High End of Outlook
05/19/201508:52:17CORRECTION: Medtronic Announces Preliminary Fourth Quarter and...
05/19/201508:35:11Current Report Filing (8-k)
05/19/201508:30:41Medtronic Announces Preliminary Fourth Quarter and Fiscal Year...
05/18/201509:00:00Data Show Medtronic Quadripolar CRT Technology Optimizes Treatment...
05/17/201510:04:024 Reasons Why MannKind Could Succeed Where Pfizer Failed
05/15/201513:30:32Medtronic TYRX(TM) Antibacterial Envelope Reduces Cardiac Device...
05/15/201508:00:00Global Clinical Trial Finds Medtronic Micra® Transcatheter Pacemaker...
05/14/201513:30:28Global Trial Finds Medtronic Micra® Transcatheter Pacemaker...
05/14/201513:30:24Medtronic Evera MRI ICD Clinical Study Meets Safety and Efficacy...
05/13/201510:48:04Dividend Stocks: What You Need to Know
05/13/201509:05:03Dividend Stocks: What You Need to Know

Medtronic and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations